Four Opportunities To Revitalize The US Biomedical Research Enterprise

The US biomedical research enterprise is renowned for its historical and ongoing scientific breakthroughs and advancements. Yet its capacity to solve complex health issues, bridge health equity gaps, and strengthen public trust is constrained by the lack of an overarching national vision, fragmented...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Health affairs (Millwood, Va.) Ročník 44; číslo 2; s. 140
Hlavní autori: Reece, E Albert, Balser, Jeffrey R, Bibbins-Domingo, Kirsten, Fraser, Claire M, Fried, Linda P, Kurth, Ann, Parikh, Sudip, Rutta, Randall L, Woolley, Mary, Yamamoto, Keith R, Zerhouni, Elias, Zoghbi, Huda Y, Dzau, Victor J
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.02.2025
Predmet:
Biomedical Research - economics
Biomedical Research - organization & administration
Biomedical Research - trends
Humans
Leadership
United States
United States
ISSN:2694-233X, 2694-233X
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The US biomedical research enterprise is renowned for its historical and ongoing scientific breakthroughs and advancements. Yet its capacity to solve complex health issues, bridge health equity gaps, and strengthen public trust is constrained by the lack of an overarching national vision, fragmented coordination for research funding, and critical workforce recruitment and retention challenges. To improve national health outcomes and retain global competitiveness, the sector must embrace new approaches. This article, part of the National Academy of Medicine's Vital Directions for Health and Health Care: Priorities for 2025 initiative, identifies four key opportunities to revitalize the biomedical research enterprise: establishing a national advisory body, bolstering the workforce, prioritizing research to reduce health disparities, and developing approaches to streamlining and coordinating federal research funding. These priorities will help the biomedical research enterprise meet twenty-first-century challenges, promote healthy longevity, and preserve US leadership in the global arena.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2694-233X
2694-233X
DOI:10.1377/hlthaff.2024.01001